0.45
-0.0425(-8.59%)
Currency In USD
| Previous Close | 0.49 |
| Open | 0.5 |
| Day High | 0.51 |
| Day Low | 0.45 |
| 52-Week High | 1.07 |
| 52-Week Low | 0.28 |
| Volume | 2.67M |
| Average Volume | 4.33M |
| Market Cap | 103.2M |
| PE | -1.74 |
| EPS | -0.26 |
| Moving Average 50 Days | 0.46 |
| Moving Average 200 Days | 0.61 |
| Change | -0.04 |
If you invested $1000 in Vaxart, Inc. (VXRT) 10 years ago, it would be worth $19.85 as of July 01, 2025 at a share price of $0.452. Whereas If you bought $1000 worth of Vaxart, Inc. (VXRT) shares 5 years ago, it would be worth $56.5 as of July 01, 2025 at a share price of $0.452.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
GlobeNewswire Inc.
Jun 13, 2025 8:52 PM GMT
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery pl
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
GlobeNewswire Inc.
Jun 11, 2025 11:30 AM GMT
- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation constructs, supporting potential for improved protection
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
GlobeNewswire Inc.
Jun 10, 2025 8:47 PM GMT
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it w